Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products

Goodwin
Contact

Goodwin

Viatris announced during its Q1 2021 earnings call that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021. These are proposed biosimilars of Sanofi’s TOUJEO and Novo Nordisk’s NOVOLOG/NOVORAPID products, respectively.  If approved, Viatris’s insulin products would be the first biosimilars to receive interchangeable designations by the FDA.

Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.